A5060842152- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Advanced Radiotherapy Techniques
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Medical Imaging and Pathology Studies
- Adrenal and Paraganglionic Tumors
- Radiation Dose and Imaging
- Prostate Cancer Treatment and Research
Institut Jules Bordet
2023-2025
Université Libre de Bruxelles
2023-2024
University of Pavia
2022
Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine (GEP-NET) lesions patients.
Abstract Background Dosimetry after radiopharmaceutical therapy with 177 Lu ( Lu-RPT) relies on quantitative SPECT/CT imaging, for which suitable reconstruction protocols are required. In this study, we characterized the first time performance of a ring-shaped CZT-based camera using two different algorithms: an ordered subset expectation maximization (OSEM) and block sequential regularized (BSREM) combined noise reduction regularization. This study lays foundations definition protocol...
The aim of this study was to assess the association among toxicity, dosimetry organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated 177 Lu-DOTATATE.
Abstract Background Radiopharmaceutical therapy (RPT) is an increasingly adopted modality for treating cancer. There evidence that the optimization of treatment based on dosimetry can improve outcomes. However, standardization clinical workflow still represents a major effort. Among many sources variability, impact using different Dose Voxel Kernels (DVKs) to generate absorbed dose (AD) maps by convolution with time‐integrated activity (TIA) distribution has not been systematically...
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its protocol is currently standardised all patients, resulting in different patient outcomes. This study investigates the variability of and organs-at-risk (kidneys red marrow) dosimetric parameters across cycles patients pancreatic intestinal NETs. Data from 37 enrolled prospective phase II (LuMEn) were analysed. Treatment...